Contraceptive Technology Update – November 1, 2008
November 1, 2008
View Issues
-
New guidance underscores DMPA's safety, efficacy in long-term use
Concerns about the effects of the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City; Medroxyprogesterone Acetate Injectable Suspension USP, Teva Pharmaceuticals USA, North Wales, PA) on bone mineral density (BMD) should not prevent clinicians from prescribing the method, nor should its use be limited to two years, according to a new committee opinion released by the American College of Obstetricians and Gynecologists (ACOG). -
Research focuses on rapid HIV testing
Is rapid HIV testing in use in your family planning facility? Findings from a 2007 survey conducted by the National Alliance of State and Territorial AIDS Directors Rapid point to "yes"; 94% of health departments indicated they use rapid HIV testing as part of health department-supported HIV testing programs. -
Time to step up HIV testing in women
Review the last three patient charts: a 19-year-old college student, a 26-year-old mother of two, and a 43-year-old woman who is newly divorced. Which women were offered screening for HIV? -
Cost-effectiveness study eyes HPV vaccine
What is the most cost-effective approach to administering vaccination against human papillomavirus (HPV)? A just-released analysis concludes vaccination will be optimized by achieving universal vaccine coverage in young adolescent girls, targeting initial "catch-up" efforts to vaccinate women younger than age 21, and by revising current screening policies. -
Extend the option of extended contraception
Take a poll among your female patients about their preferences surrounding their menstrual cycle. How many would prefer to get their periods less often? -
Treatment for PMDD? New OC regimen eyed
Review the chart for the next patient. According to her history, for about 10 days of every month, she experiences depression, marked anxiety, sudden mood shifts, persistent irritability, and bloating.